Tradr 2X Long CRML Daily ETF (CRMX) is a small, single-stock leveraged exchange-traded fund launched in January 2026 and managed by AXS Investments. It seeks 200% of the daily percentage performance of Critical Metals Corp. (CRML), a Nasdaq-listed developer of the Tanbreez heavy rare earth project in southern Greenland and the Wolfsberg lithium project in Austria. Because the mandate resets daily, the fund is a short-horizon trading vehicle rather than a buy-and-hold proxy.
Shares traded at $4.94 shortly after 1:40 p.m. ET, down $2.34, or 32.14%, from the prior session's close of $7.28. The direction was decisively lower. The immediate cause was the underlying stock: CRML dropped 15.57% to $4.12, carving out a new 52-week low, and the fund's two-times daily exposure roughly doubled that decline. No company-specific press release or filing from the ETF itself explained the move.
The dominant catalyst was sector-wide. William Blair cut USA Rare Earth (USAR) to Market Perform from Outperform on Monday morning, citing feedstock shortages at its Less Common Metals unit and Stillwater magnet plant, and pushed its revenue and margin estimates out to 2028. USAR fell about 11% and sits near its own 52-week low, dragging the entire critical-minerals complex lower. MP Materials (MP) lost roughly 4.9% and the VanEck Rare Earth/Strategic Metals ETF shed 5.7%.
The read-through matters because Critical Metals is a pre-revenue developer whose valuation rests on the same Western supply-chain narrative. When a better-capitalized peer is downgraded on feedstock and cash-burn concerns, investors extrapolate those risks across smaller, less liquid names — and Critical Metals has a fraction of the operating history and no production revenue to fall back on.
Beneath the sector move, company-specific pressure has been building for two weeks. Critical Metals closed its acquisition of European Lithium on Nov. 5, issuing roughly 90.5 million new shares; the company subsequently put shares outstanding at 194.2 million alongside about $264.5 million in cash. That share-count step-up is a large dilution overhang for a stock with a modest float.
The latest annual report also included an auditor's explanatory paragraph citing substantial doubt about the company's ability to continue as a going concern, and a chief financial officer share sale of about 66,667 shares at an average of $6.81 was disclosed. Monday marked a fourth consecutive lower session for the underlying shares. None of these items was new today, but in a falling sector they dominate the marginal buyer's thinking.
The fund's structure is central to the size of the move. With the underlying off 15.57%, a two-times daily mandate implies a decline of roughly 31%, and the fund's 32.14% drop is in line with that math once fees and intraday compounding are included. The compounding effect is more punishing over time: CRMX has fallen from $13.83 on Oct. 26 to $4.94, a loss of about 64%, while CRML is down roughly 35% over the same span. In a volatile, directionally persistent downtrend, a daily-reset leveraged product delivers materially worse than twice the underlying return.
Macro conditions were unhelpful. Major indices were lower as investors trimmed risk ahead of a closely watched semiconductor earnings report and a large anticipated technology listing, with the S&P 500 off about 1.9% and the Nasdaq 100 down 2.5%. Small caps lagged, with the Russell 2000 ETF down 1.8%. Speculative, pre-revenue materials names are typically the first to be sold in that kind of tape.
Trading in the fund was active in share-count terms but modest in dollars: roughly 27,000 shares changed hands through the first three hours, in line with the 20,000–50,000 share sessions the product has seen lately and well below the 126,900 shares traded on Nov. 13. The percentage move therefore reflects a thin order book in a two-times leveraged wrapper, where small notional flows can shift the quote sharply. The underlying stock traded several million shares, close to its recent norms, and printed a new 52-week low at $4.12 before a modest bounce. Directionally, the fund moved with the rare earth ETF and every major peer, all of which were lower; there was no divergence to suggest an idiosyncratic event.
The score runs from 0, meaning no meaningful news and a move that is routine for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 35 out of 100. The verified news was moderate at best: a peer downgrade and sector-wide de-risking, layered on known dilution and going-concern disclosures rather than a new filing or corporate announcement. The price move was unusual but not extraordinary. Today's 32.14% decline was about three times the fund's average absolute daily move of roughly 10.5% over the prior 69 sessions, and moves of this magnitude occurred four times in that window — including gains of 74.8% and 55.1%. Moderate news plus a moderately abnormal move combine into a mid-range score.
The next hard datapoint for the underlying company is its quarterly update, currently expected around Dec. 11, 2026. Investors will focus on cash burn against the roughly $264.5 million reported post-merger, progress toward the Tanbreez definitive feasibility study targeted for the fourth quarter of 2027, and first ore production pencilled in for late 2028 to early 2029 — a timeline management conditions on permitting, financing and construction. Analyst coverage is thin: the consensus rating sits at Hold with an average 12-month target near $11.95 for the underlying shares, and dispersion among individual estimates is wide.
Sector developments will likely matter more than the calendar. Chinese export-control timelines, rare earth oxide pricing and peer results all feed directly into sentiment for Western developers. The key risks are further equity issuance to fund construction, continued weakness in speculative small caps, and the mechanical erosion inherent in a daily-reset leveraged product. A stabilization in the underlying stock would slow the fund's decay, but it would not eliminate it.
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions earn a place in its curated Trending AI Robots section. Bots differ by strategy, timeframe, performance metrics and the symbols they trade, so the lineup shifts as market conditions change. Readers looking for systematic, rules-based ideas amid elevated volatility may find the current roster a useful starting point for their own research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CRMX saw its Momentum Indicator move below the 0 level on November 03, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 15 similar instances where the indicator turned negative. In 15 of the 15 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CRMX turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 6 similar instances when the indicator turned negative. In 6 of the 6 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CRMX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRMX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CRMX broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CRMX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +17.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRMX advanced for three days, in 25 of 27 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.